Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

343 ARTÍCULOS , VIENDO DEL 61 AL 75

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

Adler G, Mueller B, Articus K.

Int J Clin Pract. 2014 Apr;68(4):465-70. doi: 10.1111/ijcp.12374. Epub 2014 Mar 3.

Harnessing the immune system for treatment and detection of tau pathology

Congdon EE, Krishnaswamy S, Sigurdsson EM.

J Alzheimers Dis. 2014;40 Suppl 1(0):S113-21. doi: 10.3233/JAD-132435.

Alzheimer's disease prevention & acetyl salicylic acid: a believable story

Pomponi M, Pomponi MF.

Indian J Med Res. 2014 Jan;139(1):1-3.

Amyloid-ß-directed immunotherapy for Alzheimer's disease

Lannfelt L, Relkin NR, Siemers ER.

J Intern Med. 2014 Mar;275(3):284-95. doi: 10.1111/joim.12168.

Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study

Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S.

Int Clin Psychopharmacol. 2014 Jul;29(4):216-23. doi: 10.1097/YIC.0000000000000032.

The translocator protein as a drug target in Alzheimer's disease

Chua SW, Kassiou M, Ittner LM.

Expert Rev Neurother. 2014 Apr;14(4):439-48. doi: 10.1586/14737175.2014.896201.

Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review)

Cai Z.

Mol Med Rep. 2014 May;9(5):1533-41. doi: 10.3892/mmr.2014.2040. Epub 2014 Mar 11.

Unveiling a prescribing cascade in an older man

Rosenberg J, Rochon PA, Gill SS.

J Am Geriatr Soc. 2014 Mar;62(3):580-1. doi: 10.1111/jgs.12714.

Rationale and clinical data supporting nutritional intervention in Alzheimer's disease

Engelborghs S, Gilles C, Ivanoiu A, Vandewoude M.

Acta Clin Belg. 2014 Jan-Feb;69(1):17-24. doi: 10.1179/0001551213Z.0000000006.

Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs

Talbot K.

Neurodegener Dis Manag. 2014;4(1):31-40. doi: 10.2217/nmt.13.73.

From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?

Flaten V, Laurent C, Coelho JE, Sandau U, Batalha VL, Burnouf S, Hamdane M, Humez S, Boison D, Lopes LV, Buée L, Blum D.

Biochem Soc Trans. 2014 Apr;42(2):587-92. doi: 10.1042/BST20130229.

Considering a new paradigm for Alzheimer's disease research

Langley GR.

Drug Discov Today. 2014 Aug;19(8):1114-24. doi: 10.1016/j.drudis.2014.03.013. Epub 2014 Mar 21.

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L.

J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690.

Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail?

Persson T, Popescu BO, Cedazo-Minguez A.

Oxid Med Cell Longev. 2014;2014:427318. doi: 10.1155/2014/427318. Epub 2014 Jan 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias